Hadassah

Initiated in Israel, Clinical Trial for Innovative Pancreatic Cancer Treatment Expands to United States

Saturday, Dec 1 2012

A clinical trial with TL-118--a new treatment for metastatic pancreatic cancer--that has been ongoing at the Hadassah University Medical Center and three other oncology centers in Israel, has been expanded to the United States.

TL-118. produced by Tiltan Pharma Ltd., belongs to the family of angiogenesis-inhibiting drugs, which means it inhibits new blood vessel formation in tumors and thus cuts off their blood supply and growth. Angiogenesis, the process by which new blood vessels are formed, is a hallmark capability of cancer cells. Anti-angiogenic therapy has, therefore, emerged as a most promising strategy with solid tumors, which rely on aggressive angiogenesis for their growth.

The new United States trial will be conducted at White Plains (NY) Hospital, and will include patients who have been newly diagnosed with metastatic pancreatic cancer and not yet treated with any chemotherapy. A control group will receive standard chemotherapy, while the treatment group will receive TL-118 in addition to chemotherapy.

Dr. Dan Costin, Co-Medical Director of the White Plains Hospital cancer program and Principal Investigator for the TL-118 study at White Plains Hospital, related: "We are happy to introduce this cutting-edge therapy to our pancreatic cancer patients. Unfortunately, metastatic pancreatic cancer is a disease with very poor prognosis and we are urgently seeking new solutions that might enhance survival."

TL-118 was initially tested in a mouse model of pancreatic cancer. In these pre-clinical studies, TL-118 monotherapy inhibited tumor growth significantly, as compared to the standard-of-care chemotherapy. Moreover, when TL-118 therapy was combined with standard-of-care chemotherapy, the tumors were eliminated in all the treated animals.

To date, over 100 cancer patients have been treated with TL-118 for up to four years, according to Tiltan Pharma, jointly owned by Yissum, the Hebrew University's Technology Transfer Company, and other investors from Israel and Canada.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Friday, Sep 23 2016

2016 Graduates from 19 Countries Celebrate Hadassah’s IMPH Program

Singing "It's a Wonderful Country" in Hebrew, wearing their native dress, the members of the 41st International Master of Public Health (IMPH) program of the Hadassah-Hebrew University Braun School of Public Health and Community Medicine celebrated their graduation.

READ MORE ›
alt_text

Monday, Sep 19 2016

Hadassah Hospital Treats Terror Victims After Stabbing Attacks

This last week has brought a burst of terror attacks.

READ MORE ›
alt_text

Thursday, Sep 15 2016

“Stunning Results” Continue with Hadassah’s Stem Cell Treatment to Reverse MS

The Hadassah Medical Center is continuing to receive positive findings with its Phase II clinical trial using its unique stem cell approach to stop the progression and reversing the disabilities of multiple sclerosis.

READ MORE ›
alt_text

Thursday, Sep 15 2016

2012 Hadassah Stage-Four Melanoma Patient Thankfully Healthy

"Doctors in Florida who pronounced me ‘soon-dead’ can't believe that I'm healthy today,” said Hadassah melanoma patient Stewart Greenberg.

READ MORE ›

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Membership Questions

membership@hadassah.org

(800) 664-5646

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Missions Department

missions@hadassah.org

(800) 237-1517

Show More